SCHEMBL2903296

SCHEMBL2903296

COC(=O)c1cc([N+](=O)[O-])c(C(=O)OC)cc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.53
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
PDGFRB P09619 1/20 0.50
FGFR1 P11362 1/20 0.50
PDGFRA P16234 1/20 0.50
FLT1 P17948 1/20 0.50
FGFR3 P22607 1/20 0.50
KDR P35968 1/20 0.50
KDM4E B2RXH2 1/20 0.49
SIRT6 Q8N6T7 1/20 0.47
LMNA P02545 4/20 0.46
GAA P10253 1/20 0.44
MAPT P10636 3/20 0.44
POLB P06746 2/20 0.44
NPC1 O15118 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3898466 0.92 TDP1 (0.54) TDP1MEN1KMT2APDGFRBFGFR1
SCHEMBL1786813 0.90 MEN1 (0.51) TDP1MEN1KMT2APDGFRBFGFR1
SCHEMBL13680345 0.90 TDP1 (0.53) TDP1MEN1KMT2APDGFRBFGFR1
SCHEMBL32659719 0.88 PDGFRB (0.51) TDP1MEN1KMT2APDGFRBFGFR1
SCHEMBL1786384 0.87 TDP1 (0.51) TDP1MEN1KMT2APDGFRBFGFR1
SCHEMBL1788077 0.87 PDGFRB (0.55) TDP1MEN1KMT2APDGFRBFGFR1
SCHEMBL194902 0.86 TDP1 (0.50) TDP1MEN1KMT2APDGFRBFGFR1
SCHEMBL14809433 0.86 MEN1 (0.48) TDP1MEN1KMT2APDGFRBFGFR1
SCHEMBL12898270 0.86 TDP1 (0.50) TDP1MEN1KMT2APDGFRBFGFR1
SCHEMBL15822217 0.86 MEN1 (0.48) TDP1MEN1KMT2APDGFRBFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 US disclosed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 US disclosed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 US disclosed
EP-2240178-A1 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-10-20 EP disclosed
WO-2010059549-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2010-05-27 WO disclosed
WO-2010059549-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2010-05-27 WO disclosed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 WO disclosed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298324-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 TDP1 2164/4885MEN1 4104/4885KMT2A 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.